MedTrace Logo

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

NCT02411344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-09-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the activity of molecular response in endocrine sensitive breast cancer HER2+/HR+ patients treated with Pertuzumab-trastuzumab plus Ietrozole.

Conditions

  • Endocrine Sensitive HER2+/HR+ Breast Cancer

Interventions

DRUG

Pertuzumab

* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles * Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle * Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).

Sponsors & Collaborators

  • Association for Translational Research in Oncology (AS.T.R.O.)

    collaborator UNKNOWN

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Valentina Guarneri, MD; PhD · Medical Oncology 2, Istituto Oncologico Veneto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2018-01-12
Completion
2018-01-12

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02411344 on ClinicalTrials.gov